Myriad Pharmaceuticals Inc. (MYRX) Announces Acquisition of Javelin Pharmaceuticals Inc.
Myriad Pharmaceuticals Inc. is a biotechnology company focused on the development of drugs for cancer, HIV and other medical conditions. The company today announced an acquisition agreement with Javelin Pharmaceuticals (AMEX: JAV), a company engaged in innovative technologies to develop new drugs for the pain management market. Javelin has one marketed drug in the U.K., Dyloject, an injectable treatment for postoperative pain, as well as two drug candidates in U.S. advanced clinical development. On December 2, 2009, Javelin submitted a New Drug Application with the FDA for Dyloject. Myriad’s acquisition of Javelin complements Myriad’s portfolio of product candidates, and is…